Riggs Asset Managment Co. Inc. Galectin Therapeutics Inc Transaction History

Riggs Asset Managment Co. Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Jul 27, 2018	SELL	$3.16 - $9.16 $3,160 - $9,160	-1,000 Closed	0 $0
Q3 2017 Oct 30, 2017	BUY	$1.67 - $2.3 $1,670 - $2,300	1,000	1,000 $2,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $61.8M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Riggs Asset Managment Co. Inc., based on Form 13F filings with the SEC.

Stay updated on Riggs Asset Managment Co. Inc. with notifications on news.